**Erythropoietin single nucleotide polymorphisms are associated with anemia and dyslipidemia in a cardiovascular disease population.**

Victoria Northrup1,2,6, Ashley L. Eadie1,2,6, Victoria L. Nelson1,2,6 , Kenneth D’Souza3,6, Ansar Hassan3,6, Thomas Pulinilkunnil2,4,6, Petra Kienesberger2,4,6, Jean-Francois Légaré3,6, Jeremy A. Simpson5,6, Keith R. Brunt1,2,3,6

1Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada

2Dalhousie Medicine New Brunswick, Saint John, New Brunswick, Canada

3Departments of Cardiology & Cardiac Surgery, New Brunswick Heart Center,

Saint John Regional Hospital, Saint John, New Brunswick, Canada

4Department of Biochemistry and Molecular Biology, Dalhousie University, Halifax, Nova Scotia, Canada

5Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, ON, Canada

6IMPART investigator team Canada (https://impart.team/)

**Supplemental Material**

**Supplemental Table 1- Erythropoietin SNP associations**

|  |  |  |  |
| --- | --- | --- | --- |
| SNP | Allele | Phenotype | References |
| rs1617640 | G | Higher Hct in healthy blood donors | 1 |
| Diabetic microvascular complications | 2–10 |
| Decreased overall mortality in diabetes | 11 |
| Higher Hb, Hct, RBC count and earlier onset PAD | 12 |
| MDS and ALL | 13 |
| Improved cognitive performance in Schizophrenia | 14 |
| T | Anemia in T2DM | 15 |
| Renal dysfunction following cardiac surgery | 16 |
| Improved response to platinum-based chemotherapy in NSCLC | 17 |
| rs507392 | C | Diabetic microvascular complications | 2,4,5,18 |
| Decreased overall mortality in diabetes | 11 |
| rs551238 | C | Higher Hct in healthy blood donors | 1 |
| Diabetic microvascular complications | 1,2,4–7,18,19 |
| Pre-term infant brain injury | 20 |

SNP=Single Nucleotide Polymorphism, Hct=hematocrit, Hb=hemoglobin, RBC=red blood cell, PAD=peripheral artery disease, MDS=myelodysplatic syndrome, ALL=acute lymphoblastic leukemia, T2DM=type 2 diabetes mellites, NSCLC=non-small cell lung cancer

**Supplemental Table 2 - Demographics and clinical parameters of the OPOS cohort by disorder**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Total** | **Anemia** | | | **Dyslipidemia** | | | **Hypertension** | | |
|  | (n=95) | Cases (n=31) | Controls (n=64) | p-value | Cases (n=66) | Controls (n=29) | p-value | Cases (n=70) | Controls (n=25) | p-value |
| Age (years) | 63.5 ± 6.6 | 65.1 ± 5.8 | 62.7 ± 6.8 | 0.52 | 64.3 ± 6.3 | 61.7 ± 6.8 | **0.03** | 64.2 ± 6.9 | 61.6 ± 5.3 | **0.04** |
| Males | 65 (68%) | 15 (48%) | 50 (78%) | **0.0035** | 49 (74%) | 16 (55%) | **0.045** | 53 (76%) | 12 (48%) | **0.01** |
| Females | 30 (32%) | 16 (52%) | 14 (22%) | 17 (26%) | 13 (45%) | 17 (24%) | 13 (52%) |
| BMI (kg/m2) | 31.8 ± 7.3 | 34.4 ± 9.4 | 30.5± 5.6 | **0.007** | 31.3 ± 6.0 | 32.7 ± 9.6 | 0.70 | 31.4 ± 6.3 | 32.8 ± 9.6 | 0.10 |
| Normal | 14 (15%) | 4 (13%) | 10 (16%) | 0.19 | 9 (14%) | 5 (17%) | 0.86 | 11 (16%) | 3 (12%) | 0.83 |
| Pre-obese | 31 (33%) | 8 (26%) | 23 (36%) | 22 (33%) | 9 (31 %) | 22 (31%) | 9 (36%) |
| Obese 1 | 22 (23%) | 6 (19%) | 16 (25%) | 17 (26%) | 5 (17%) | 16 (23%) | 6 (24%) |
| Obese 2 | 13 (14%) | 4 (13%) | 9 (14%) | 8 (12%) | 5 (17%) | 11 (16%) | 2 (8%) |
| Obese 3 | 15 (16%) | 9 (29%) | 6 (9%) | 10 (15%) | 5 (17%) | 10 (14%) | 5 (20%) |
| NYHA 1 | 18 (19%) | 4 (14%) | 14 (22%) | 0.42 | 8 (12%) | 10 (37%) | **0.006** | 13 (19%) | 5 (22%) | 0.91 |
| 2 | 39 (42%) | 11 (38%) | 28 (44%) | 31 (47%) | 8 (30%) | 29 (41%) | 10 (43%) |
| 3 | 25 (27%) | 11 (38%) | 14 (22%) | 16 (24%) | 9 (33%) | 19 (27%) | 6 (26%) |
| 4 | 11 (12%) | 3 (10%) | 8 (13%) | 11 (17%) | 0 (0%) | 9 (13%) | 2 (9%) |
| LVEF (%) | 59.8 ± 11.2 | 60.9 ± 10.7 | 59.3 ± 11.4 | 0.99 | 58.0 ± 11.9 | 64.0 ± 7.8 | 0.07 | 60.5 ± 11.3 | 58.1 ± 10.7 | 0.26 |
| LVEDP (mmHg) | 18.0 ± 6.6 | 18.8 ± 6.4 | 17.7 ± 6.7 | 0.052 | 18.6 ± 6.7 | 16.6 ± 6.4 | 0.10 | 18.7 ± 7.0 | 15.7 ± 4.8 | 0.10 |
| Hemoglobin (g/L) | 134.8 ± 14.7 | 117.8 ± 11.5 | 142.6 ± 7.8 | **<0.0001** | 134.8 ± 14.6 | 135.0 ± 14.8 | 0.60 | 134.9 ± 15.2 | 134.7 ± 12.9 | 0.82 |
| Hematocrit (L/L) | 0.40 ± 0.04 | 0.35 ± 0.03 | 0.42 ± 0.02 | **<0.0001** | 0.40 ± 0.04 | 0.40 ± 0.04 | 0.46 | 0.40 ± 0.04 | 0.40 ± 0.03 | 0.75 |
| MCV(fL) | 90.1 ± 4.3 | 88.2 ± 4.7 | 90.9 ± 3.8 | 0.052 | 89.4 ± 4.2 | 91.9 ± 3.9 | 0.054 | 90.3 ± 4.3 | 89.6 ± 4.2 | 0.55 |
| HbA1c (%) | 6.1 ± 1.0 | 6.2 ± 1.3 | 6.0 ± 0.9 | 0.68 | 6.2 ± 1.1 | 5.8 ± 0.8 | 0.29 | 6.1 ± 1.1 | 5.8 ± 0.8 | 0.42 |
| Chol (mmol/L) | 4.1 ± 1.2 | 4.0 ± 1.1 | 4.1 ± 1.2 | 0.86 | 3.9 ± 1.1 | 4.5 ± 1.1 | 0.07 | 3.9 ± 1.2 | 4.4 ± 1.1 | 0.52 |
| HDL (mmol/L) | 1.2 ± 0.4 | 1.2 ± 0.4 | 1.2 ± 0.3 | 0.66 | 1.2 ± 0.3 | 1.4 ± 0.3 | 0.057 | 1.2 ± 0.4 | 1.3 ± 0.3 | 0.26 |
| LDL (mmol/L) | 2.1 ± 0.9 | 2.1 ± 0.9 | 2.1 ± 0.9 | 0.89 | 2.0 ± 0.8 | 2.5 ± 1.0 | **0.03** | 2.0 ± 0.9 | 2.5 ± 1.0 | 0.51 |
| LDL/HDL | 1.8 ± 0.8 | 1.7 ± 0.8 | 1.8 ± 0.7 | 0.63 | 1.7 ± 0.7 | 1.9 ± 0.7 | 0.38 | 1.7 ± 0.7 | 1.9 ± 0.8 | 0.92 |
| Non-HDL (mmol/L) | 2.9 ± 1.1 | 2.8 ± 1.0 | 2.9 ± 1.1 | 0.75 | 2.7 ±1.1 | 3.1 ± 1.0 | 0.17 | 2.8 ± 1.1 | 3.1 ± 1.0 | 0.79 |
| Trigly (mmol/L) | 1.6 ± 1.1 | 1.8 ± 1.2 | 1.6 ± 1.0 | 0.58 | 1.7 ± 1.2 | 1.3 ± 0.6 | 0.27 | 1.7 ± 1.2 | 1.4 ± 0.6 | 0.59 |
| RBC (x10^12/L) | 4.4 ± 0.4 | 4.0 ± 0.4 | 4.6 ± 0.3 | **<0.0001** | 4.5 ± 0.4 | 4.4 ± 0.4 | 0.81 | 4.4 ± 0.5 | 4.5 ± 0.3 | 0.53 |
| WBC (x10^9/L) | 7.4 ± 2.4 | 7.8 ± 3.2 | 7.2 ± 1.9 | 0.37 | 7.6 ± 2.6 | 6.8 ± 1.8 | 0.44 | 7.4 ± 2.4 | 7.3 ± 2.5 | 0.46 |
| Platlets (x10^9/L) | 205.5 ± 53.9 | 209.0 ± 72.2 | 203.9 ± 43.1 | 0.56 | 209.5 ± 57.1 | 195.8 ± 43.7 | 0.38 | 205.7 ± 56.5 | 204.9 ± 45.4 | 0.91 |
| Neutro (x10^9/L) | 4.9 ± 2.2 | 5.5 ± 3.3 | 4.7 ± 1.5 | 0.21 | 5.1 ± 2.3 | 4.5 ± 1.8 | 0.56 | 5.0 ± 2.2 | 4.8 ± 2.2 | 0.62 |
| Lympho (x10^9/L) | 1.7 ± 0.6 | 1.5 ± 0.7 | 1.7 ± 0.6 | 0.23 | 1.7 ± 0.6 | 1.6 ± 0.6 | 0.99 | 1.6 ± 0.7 | 1.7 ± 0.6 | 0.20 |
| NLR | 3.9 ± 5.1 | 6.1 ± 8.5 | 2.9 ± 1.2 | 0.11 | 3.8 ± 4.6 | 4.1 ± 6.0 | 0.47 | 4.2 ± 5.7 | 3.1 ± 2.1 | 0.55 |
| Troponin (ng/L) | 785.2 ±590.3 | 878.6 ± 823.7 | 740.9 ± 431.0 | 0.61 | 694.1 ± 428.4 | 999.1 ± 818.6 | **0.03** | 794.3 ± 637.3 | 758.6 ± 420.7 | 0.51 |
| Creatine (mmol/L) | 92.9 ± 71.1 | 113.3 ± 121.6 | 83.7 ± 19.4 | 0.22 | 97.8 ± 82.6 | 81.1 ± 22.9 | 0.25 | 89.0 ± 26.4 | 105.1 ± 134.6 | 0.22 |
| Urea (mmol/L) | 6.7 ± 2.5 | 7.2 ± 3.3 | 6.5 ± 2.1 | 0.054 | 7.0 ± 2.7 | 6.1 ± 2.0 | 0.07 | 7.0 ± 2.3 | 5.8 ± 2.8 | 0.08 |

**Supplemental Table 2 cont’d - Demographics and clinical parameters of the OPOS cohort by disorder**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **HFpEF** | | | **T2DM** | | |
|  | Cases (n=77) | Controls (n=18) | p-value | Cases (n=33) | Controls (n=62) | p-value |
| Age (years) | 63.9 ± 6.8 | 61.9 ± 5.5 | 0.25 | 64.6 ± 5.5 | 63.0 ± 7.1 | 0.17 |
| Males | 53 (69%) | 12 (67%) | 0.86 | 26 (81%) | 36 (59%) | **0.040** |
| Females | 24 (31%) | 6 (33%) | 6 (19%) | 25 (41%) |
| BMI (kg/m2) | 30.9 ± 6.2 | 35.5 ± 10.0 | **0.016** | 33.3 ± 6.0 | 30.9 ± 7.8 | **0.010** |
| Normal | 12 (16%) | 2 (11%) | 0.11 | 1 (3%) | 13 (21%) | 0.14 |
| Pre-obese | 29 (38%) | 2 (11%) | 10 (30%) | 21 (34%) |
| Obese 1 | 16 (21%) | 6 (33%) | 10 (30%) | 12 (19%) |
| Obese 2 | 8 (10%) | 5 (38%) | 5 (15%) | 8 (13%) |
| Obese 3 | 12 (16%) | 3 (17 %) | 7 (21%) | 8 (13%) |
| NYHA 1 | 14 (18%) | 4 (25%) | 0.85 | 5 (15%) | 13 (22%) | 0.46 |
| 2 | 32 (42%) | 7 (44%) | 12 (36 %) | 27 (45%) |
| 3 | 22 (29%) | 3 (19%) | 12 (36%) | 13 (22%) |
| 4 | 9 (12%) | 2 (13%) | 4 (12%) | 7 (12%) |
| LVEF (%) | 63.9 ±7.4 | 42.6 ± 7.6 | **<0.0001** | 56.7 ± 11.3 | 61.5 ± 10.7 | 0.10 |
| LVEDP (mmHg) | 17.4 ± 6.5 | 20.4 ± 6.8 | 0.11 | 18.8 ± 6.6 | 17.6 ± 6.6 | 0.35 |
| Hemoglobin (g/L) | 135.0 ± 14.6 | 134.3 ± 14.9 | 0.86 | 132.9 ± 14.9 | 135.9 ± 14.4 | 0.24 |
| Hematocrit (L/L) | 0.40 ± 0.04 | 0.40 ± 0.04 | 0.71 | 0.39 ± 0.04 | 0.40 ± 0.04 | 0.22 |
| MCV(fL) | 90.1 ± 4.3 | 90.1 ± 3.9 | 0.98 | 89.5 ± 4.1 | 90.4 ± 4.3 | 0.22 |
| HbA1c (%) | 6.0 ± 1.0 | 6.4 ± 0.9 | 0.20 | 7.0 ± 1.2 | 5.6 ± 0.3 | **<0.0001** |
| Chol (mmol/L) | 4.1 ± 1.2 | 3.9 ± 1.1 | 0.62 | 3.6 ± 0.9 | 4.3 ± 1.2 | **0.012** |
| HDL (mmol/L) | 1.2 ± 0.4 | 1.2 ± 0.2 | 0.69 | 1.1 ± 0.4 | 1.3 ± 0.3 | **0.045** |
| LDL (mmol/L) | 2.1 ± 0.9 | 2.1 ± 1.1 | 0.84 | 1.7 ± 0.7 | 2.3 ± 1.0 | **0.016** |
| LDL/HDL | 1.8 ± 0.7 | 1.8 ± 0.9 | 0.70 | 1.6 ± 0.7 | 1.9 ± 0.7 | 0.60 |
| Non-HDL (mmol/L) | 2.9 ± 1.1 | 2.8 ± 1.1 | 0.82 | 2.5 ± 0.8 | 3.0 ± 1.1 | 0.06 |
| Trigly(mmol/L) | 1.6 ± 1.1 | 1.5 ± 0.7 | 0.54 | 1.9 ± 1.2 | 1.5 ± 0.9 | 0.71 |
| RBC (x10^12/L) | 4.5 ± 0.4 | 4.4 ± 0.5 | 0.63 | 4.4 ± 0.4 | 4.5 ± 0.4 | 0.58 |
| WBC (x10^9/L) | 7.3 ± 2.3 | 7.7 ± 2.9 | 0.57 | 8.0 ± 2.9 | 7.1 ± 2.0 | 0.26 |
| Platelets (x10^9/L) | 204.9 ± 56.6 | 208.1 ± 38.4 | 0.83 | 218.2 ± 68.9 | 198.5 ± 42.0 | 0.36 |
| Neutro (x10^9/L) | 4.9 ± 2.2 | 5.1 ± 2.5 | 0.75 | 5.5 ± 2.7 | 4.6 ± 1.8 | 0.15 |
| Lympho (x10^9/L) | 1.7 ± 0.7 | 1.8 ± 0.5 | 0.56 | 1.7 ± 0.7 | 1.7 ± 0.6 | 0.55 |
| NLR | 4.0 ± 5.6 | 3.1 ± 1.7 | 0.51 | 4.7 ± 6.1 | 3.5 ± 4.3 | 0.25 |
| Troponin (ng/L) | 838.1 ± 616.9 | 509.6 ± 300.8 | 0.057 | 754.1 ± 709.1 | 809.2 ± 520.8 | 0.42 |
| Creatine (mmol/L) | 85.7 ± 24.0 | 127.7 ± 158.5 | **0.032** | 110.8 ± 112.8 | 83.1 ± 23.6 | 0.25 |
| Urea (mmol/L) | 6.6 ± 2.1 | 7.2 ± 3.8 | 0.47 | 7.7 ± 3.1 | 6.2 ± 1.9 | **0.028** |

NYHA=New York Heart Association, BMI=Body mass index, HDL=high-density lipoprotein, LDL=low-density lipoprotein, LVEF=Left ventricular ejection fraction, LVEDP=left ventricular end diastolic pressure, HFpEF=Heart failure with preserved ejection fraction, T2DM=type 2 diabetes mellitus, REB=red blood cells (erythrocytes), WBC=white blood cells (leukocytes), Neutro=Neutrophiles, Lympho= Lymphocytes, NLR=Neutrophiles Lymphocytes ratio. p-value for continuous variable (BMI, LVEF, LVEDP, Hemoglobin, Hematocrit, HbA1c, Chol=Cholesterol, HDL, LDL, Trigly=Triglycerides, RBC, Troponin, Creatine, WBC, Neutrophiles, Lymphocytes, NLR, Urea) expressed as mean ±SD; p-value calculated using t-test. Categorical variable (Sex, BMI Class, and NYHA) expressed as number of cases (percentage of group); p-value calculated using Chi-square test. Significant p-values of <0.05 are bolded.

A screenshot of a computer

Description automatically generated

**Supplemental Figure 1 - EPO SNPs show a high degree of linkage disequilibrium.**

A) The linkage coefficient (D’), R-value and p-value are provided for each combination. Greyed boxes are duplicated combinations or analysis between the same SNPs and were therefore not analyzed. Red boxes show combinations, with darker shades indicating greater degrees of linkage disequilibrium. B) EPO gene layout with SNP locations.

**Supplemental Table 3-rs1617640 demographics and clinical parameters.**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Genotype | | | p-value | | |
|  | AA (n=38) | AC (n=32) | CC (n=24) | AA-AC | AA-CC | AC-CC |
| Age (years) | 64.1 ± 6.1 | 63.4 ± 6.8 | 62.6 ± 7.0 | 0.68 | 0.41 | 0.68 |
| Males (%) | 29 (76%) | 20 (63%) | 15 (63%) | 0.20 | 0.24 | 0.99 |
| Females | 9 (24%) | 12 (38%) | 9 (38%) |
| BMI (kg/m2) | 29.7 ± 5.3 | 31.8 ± 6.9 | 34.9 ± 9.3 | 0.16 | **0.007** | 0.16 |
| Normal | 7 (18%) | 5 (16%) | 2 (8%) | 0.40 | **0.008** | 0.40 |
| Pre-obese | 14 (37%) | 10 (31%) | 7 (29%) |
| Obese 1 | 12 (32%) | 7 (22%) | 2 (8%) |
| Obese 2 | 3 (8%) | 4 (13%) | 6 (25%) |
| Obese 3 | 2 (5%) | 6 (19%) | 7 (29%) |
| NYHA 1 | 8 (21%) | 6 (19%) | 4 (17%) | 0.46 | 0.67 | 0.27 |
| 2 | 17 (45%) | 9 (39%) | 12 (52%) |
| 3 | 8 (21%) | 11 (35%) | 6 (26%) |
| 4 | 5 (13%) | 5 (16%) | 1 (4%) |
| LVEF (%) | 58.8 ± 11.8 | 61.4 ± 10.2 | 59.2 ± 11.3 | 0.32 | 0.88 | 0.45 |
| LVEDP (mmHg) | 17.0 ± 6.7 | 17.6 ± 7.0 | 20.5 ± 5.3 | 0.72 | 0.056 | 0.13 |
| Hemoglobin (g/L) | 137.3 ± 9.1 | 135.3 ± 18.6 | 129.6 ± 15.0 | 0.56 | **0.017** | 0.24 |
| Hematocrit (L/L) | 0.40 ± 0.03 | 0.40 ± 0.05 | 0.39 ± 0.04 | 0.77 | 0.08 | 0.32 |
| MCV (fL) | 90.4 ± 3.7 | 90.2 ± 4.4 | 89.5 ± 5.0 | 0.81 | 0.44 | 0.63 |
| HbA1c (%) | 6.2 ± 1.2 | 5.9 ± 0.8 | 5.9 ± 0.7 | 0.25 | 0.31 | 0.92 |
| Cholesterol(mmol/L) | 4.2 ± 1.3 | 3.7 ± 1.1 | 4.4 ± 1.0 | 0.06 | 0.59 | **0.019** |
| HDL (mmol/L) | 1.2 ± 0.4 | 1.2 ± 0.4 | 1.3 ± 0.3 | 0.79 | 0.11 | 0.09 |
| LDL (mmol/L) | 2.2 ± 0.9 | 1.8 ± 0.9 | 2.4 ± 0.9 | 0.10 | 0.33 | **0.018** |
| LDL/HDL | 1.9 ± 0.8 | 1.6 ± 0.7 | 1.9 ± 0.8 | 0.13 | 0.80 | 0.11 |
| Non-HDL (mmol/L) | 3.0 ±1.2 | 2.5 ± 0.9 | 3.0 ± 1.0 | **0.046** | 0.99 | **0.045** |
| TG (mmol/L) | 1.9 ± 1.4 | 1.5 ± 0.7 | 1.3 ± 0.5 | 0.14 | 0.07 | 0.40 |
| RBC (x10^12/L) | 4.5 ± 0.3 | 4.4 ± 0.5 | 4.4 ± 0.4 | 0.82 | 0.32 | 0.60 |
| WBC (x10^9/L) | 7.1 ±2.1 | 7.4 ± 2.8 | 7.9 ±2.3 | 0.72 | 0.22 | 0.49 |
| Platelets (x10^9/L) | 207.0 ± 46.4 | 208.3 ± 64.6 | 199.8 ± 50.2 | 0.92 | 0.58 | 0.61 |
| Neutro (x10^9/L) | 4.6 ± 1.6 | 4.9 ± 2.7 | 5.5 ± 2.4 | 0.49 | 0.07 | 0.40 |
| Lympho (x10^9/L) | 1.7 ± 0.6 | 1.6 ± 0.6 | 1.6 ± 0.8 | 0.51 | 0.30 | 0.61 |
| NLR | 2.8 ± 1.0 | 3.5 ± 3.6 | 6.3 ± 8.7 | 0.22 | **0.018** | 0.12 |
| Troponin (ng/L) | 756.8 ± 521.6 | 796.7 ± 665.4 | 815.7 ± 599.2 | 0.79 | 0.70 | 0.91 |
| Creatine (mmol/L) | 85.2 ± 17.4 | 103.6 ± 117.8 | 92.4 ± 31.0 | 0.35 | 0.25 | 0.66 |
| Urea (mmol/L) | 6.3 ± 1.9 | 7.0 ± 2.7 | 7.1 ± 3.0 | 0.24 | 0.21 | 0.86 |

NYHA=New York Heart Association, BMI=Body mass index, HDL=high-density lipoprotein, LDL=low-density lipoprotein, LVEF=Left ventricular ejection fraction, LVEDP=left ventricular end diastolic pressure, HFpEF=Heart failure with preserved ejection fraction, T2DM=type 2 diabetes mellitus, TG=triglycerides, RBC=red blood cells, WBC=white blood cells (leukocytes), Neutro=Neutrophiles, Lympho= Lymphocytes, NLR=Neutrophiles Lymphocytes ratio. p-value for continuous variable (BMI, LVEF, LVEDP, Hemoglobin, Hematocrit, HbA1c, Cholesterol, HDL, LDL, Triglycerides, RBC, Troponin, Creatine, WBC, Neutrophiles, Lymphocytes, NLR, Urea) expressed as mean ±SD, p-value calculated using t-test. Categorical variable (Sex, BMI Class, and NYHA) expressed as number of cases (percentage of group), p-value calculated using Chi-square test. Significant p-value of <0.05 are bolded.

A screenshot of a computer screen

Description automatically generated


**Supplemental Figure 2- rs1617640 genotype correlation with clinical parameters.**

The clinical parameter is indicated above each graph with normal and abnormal ranges indicated within the graph by background colour. Outliers removed from statistical analysis (by ROUT test or outside limits of detection of the assay) are indicated by circles. Hb=hemoglobin, Hct=hematocrit, HDL=high-density lipoprotein, LDL=low-density lipoprotein, LVEF=left ventricular ejection fraction, LVEDP=left ventricular end diastolic pressure, and NLR=neutrophil to lymphocyte ratio. Statistical significance determined by student t-test.

**Supplemental Table 4 - rs507392 demographics and clinical parameters**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Genotype | | | p-value | | |
|  | AA (n=36) | AG (n=31) | GG (n=19) | AA-AG | AA-GG | AG-GG |
| Age (years) | 63.8 ± 6.1 | 63.4 ± 7.3 | 63.9 ± 6.9 | 0.89 | 0.86 | 0.80 |
| Males | 29 (81%) | 21 (68%) | 7 (37%) | 0.22 | 0.15 | 0.73 |
| Females | 7 (19%) | 10 (32%) | 12 (63%) |
| BMI (kg/m2) | 29.4 ± 5.1 | 31.1 ± 6.3 | 32.1 ± 6.6 | 0.23 | 0.10 | 0.60 |
| Normal | 7 (19%) | 5 (16%) | 2 (11%) | 0.29 | **0.036** | 0.71 |
| Pre-obese | 13 (36%) | 11 (35%) | 7 (37%) |
| Obese 1 | 12 (33%) | 6 (19%) | 2 (11%) |
| Obese 2 | 3 (8%) | 4 (13%) | 5 (26%) |
| Obese 3 | 1 (3%) | 5 (16%) | 3 (16%) |
| NYHA 1 | 8 (22%) | 6 (19%) | 4 (21%) | 0.68 | 0.79 | 0.63 |
| 2 | 15 (42%) | 10 (32%) | 9 (47%) |
| 3 | 8 (22%) | 11 (35%) | 5 (26%) |
| 4 | 5 (14%) | 4 (13%) | 1 (5%) |
| LVEF (%) | 59.0 ± 12.0 | 61.4 ± 10.3 | 60.5 ± 11.4 | 0.38 | 0.66 | 0.76 |
| LVEDP (mmHg) | 17.1 ± 6.7 | 17.7 ± 7.1 | 20.4 ± 4.9 | 0.75 | 0.09 | 0.18 |
| Hemoglobin (g/L) | 138.0 ± 8.8 | 137.1 ± 16.8 | 133.1 ± 13.1 | 0.78 | 0.11 | 0.39 |
| Hematocrit (L/L) | 0.41 ± 0.03 | 0.41 ± 0.05 | 0.40 ± 0.03 | 0.96 | 0.32 | 0.51 |
| MCV (fL) | 90.7 ± 3.4 | 90.4 ± 4.0 | 90.5 ± 4.0 | 0.75 | 0.82 | 0.96 |
| HbA1c (%) | 6.2 ± 1.2 | 5.9 ± 0.8 | 5.9 ± 0.7 | 0.20 | 0.25 | 0.92 |
| Cholesterol (mmol/L) | 4.2 ± 1.3 | 3.7 ± 1.0 | 4.6 ± 0.9 | 0.07 | 0.33 | **0.005** |
| HDL (mmol/L) | 1.2 ± 0.4 | 1.2 ± 0.4 | 1.3 ± 0.3 | 0.86 | 0.14 | 0.11 |
| LDL (mmol/L) | 2.2 ± 0.9 | 1.8 ± 0.8 | 2.6 ± 0.9 | 0.11 | 0.16 | **0.005** |
| LDL/HDL | 1.9 ± 0.8 | 1.6 ± 0.7 | 2.0 ± 0.7 | 0.15 | 0.51 | 0.051 |
| Non-HDL (mmol/L) | 3.1 ± 1.2 | 2.5 ± 0.9 | 3.2 ± 0.9 | **0.046** | 0.63 | **0.011** |
| TG (mmol/L) | 1.9 ± 1.4 | 1.4 ± 0.7 | 1.4 ± 0.6 | 0.057 | 0.11 | 0.98 |
| RBC (x10^12/L) | 4.5 ± 0.3 | 4.5 ± 0.5 | 4.4 ± 0.4 | 0.92 | 0.54 | 0.63 |
| WBC (x10^9/L) | 7.2 ± 2.1 | 7.1 ± 2.4 | 7.9 ±2.3 | 0.88 | 0.25 | 0.25 |
| Platelets (x10^9/L) | 208.0 ± 47.5 | 206.2 ± 63.2 | 202.4 ± 52.1 | 0.89 | 0.69 | 0.83 |
| Neutrophiles (x10^9/L) | 4.6 ± 1.7 | 4.7 ± 2.3 | 5.5 ± 2.4 | 0.85 | 0.09 | 0.22 |
| Lymphocytes (x10^9/L) | 1.8 ± 0.6 | 1.7 ± 0.6 | 1.6 ± 0.8 | 0.56 | 0.48 | 0.78 |
| NLR | 2.8 ± 1.0 | 3.3 ± 3.6 | 6.3 ± 9.4 | 0.36 | **0.031** | 0.12 |
| Troponin (ng/L) | 782.2 ± 523.4 | 795.3 ± 663.0 | 859.6 ± 631.2 | 0.93 | 0.64 | 0.74 |
| Creatine (mmol/L) | 86.1 ± 17.4 | 81.8 ± 25.2 | 91.6 ± 30.1 | 0.42 | 0.40 | 0.23 |
| Urea (mmol/L) | 6.4 ± 1.9 | 6.4 ± 1.7 | 7.2 ± 2.9 | 0.99 | 0.23 | 0.23 |

NYHA=New York Heart Association, BMI=Body mass index, HDL=high-density lipoprotein, LDL=low-density lipoprotein, LVEF Left ventricular ejection fraction, LVEDP=left ventricular end diastolic pressure, HFpEF=Heart failure with preserved ejection fraction, T2DM=type 2 diabetes mellitus, TG=triglycerides, RBC=red blood cells, WBC=white blood cells (leukocytes), Neutro=Neutrophiles, Lympho= Lymphocytes, NLR=Neutrophiles Lymphocytes ratio. p-value for continuous variable (BMI, LVEF, LVEDP, Hemoglobin, Hematocrit, HbA1c, Cholesterol, HDL, LDL, Triglycerides, RBC, Troponin, Creatine, WBC, Neutrophiles, Lymphocytes, NLR, Urea) expressed as mean ±SD, p-value calculated using student t-test. Categorical variable (Sex, BMI Class, and NYHA expressed as number of cases (percentage of group), p-value calculated using Chi-square test. Significant p-value of <0.05 are bolded.




**Supplemental Figure 3- rs507392 genotype correlations with clinical parameters.**

Clinical parameters are indicated above each graph, with normal and abnormal ranges indicated within the graph by background colour. Outliers removed from statistical analysis (by ROUT test or outside limits of detection of the assay) are indicated by circles. Hb=hemoglobin, Hct=hematocrit, HDL=high-density lipoprotein, LDL=low-density lipoprotein, LVEF=left ventricular ejection fraction, LVEDP=left ventricular end diastolic pressure, and NLR=neutrophile to lymphocyte ratio. Statistical significance was determined by student t-test.

**Supplemental Table 5 - rs551238 demographics and clinical parameters**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Genotypes | | | p-value | | |
|  | TT | TG | GG | TT-TG | TT-GG | TG-GG |
| Age (years) | 63.9 ± 6.0 | 63.4 ± 7.1 | 63.6 ± 7.3 | 0.74 | 0.89 | 0.90 |
| Males | 32 (80%) | 20 (65%) | 11 (65%) | 0.14 | 0.21 | 0.98 |
| Females | 8 (20%) | 11 (35%) | 6 (35%) |
| BMI (kg/m2) | 30.0 ± 6.0 | 31.3 ± 6.6 | 32.9 ± 6.5 | 0.38 | 0.11 | 0.44 |
| Normal | 7 (18%) | 5 (16%) | 2 (12%) | 0.19 | 0.06 | 0.19 |
| Pre-obese | 14 (35%) | 11 (35%) | 5 (29%) |
| Obese 1 | 14 (35%) | 5 (16%) | 2 (12%) |
| Obese 2 | 3 (8%) | 4 (13%) | 5 (29%) |
| Obese 3 | 2 (5%) | 6 (19%) | 3 (18%) |
| NYHA 1 | 9 (23%) | 7 (23%) | 2 (12%) | 0.88 | 0.83 | 0.83 |
| 2 | 16 (41%) | 10 (32%) | 8 (47%) |
| 3 | 9 (23%) | 9 (29%) | 6 (35%) |
| 4 | 5 (13%) | 5 (16%) | 1 (6%) |
| LVEF (%) | 59.7 ± 11.8 | 61.7 ± 10.1 | 58.9 ± 11.5 | 0.45 | 0.82 | 0.39 |
| LVEDP (mmHg) | 16.8 ± 6.5 | 18.1 ± 7.1 | 19.9 ± 5.1 | 0.42 | 0.11 | 0.42 |
| Hemoglobin (g/L) | 139.1 ± 9.4 | 136.0 ± 15.5 | 131.9 ± 15.6 | 0.31 | 0.04 | 0.40 |
| Hematocrit (L/L) | 0.41 ± 0.03 | 0.40 ± 0.04 | 0.39 ± 0.04 | 0.48 | 0.11 | 0.46 |
| MCV (fL) | 90.8 ± 3.3 | 89.8 ± 4.3 | 91.0 ± 4.1 | 0.29 | 0.83 | 0.36 |
| HbA1c (%) | 6.3 ± 1.3 | 5.9 ± 0.8 | 5.9 ± 0.8 | 0.17 | 0.26 | 0.97 |
| Cholesterol (mmol/L) | 4.2 ± 1.2 | 3.7 ± 1.1 | 4.4 ± 1.0 | 0.06 | 0.57 | **0.031** |
| HDL (mmol/L) | 1.2 ± 0.4 | 1.2 ± 0.4 | 1.3 ± 0.3 | 0.77 | 0.13 | 0.09 |
| LDL (mmol/L) | 2.2 ± 0.9 | 1.9 ± 0.9 | 2.4 ± 0.9 | 0.14 | 0.45 | 0.06 |
| LDL/HDL | 1.9 ± 0.8 | 1.6 ± 0.6 | 1.9 ± 0.8 | 0.12 | 0.97 | 0.21 |
| Non-HDL (mmol/L) | 3.1 ± 1.2 | 2.5 ± 0.9 | 3.1 ± 1.0 | **0.045** | 0.97 | 0.06 |
| TG(mmol/L) | 1.9 ± 1.4 | 1.4 ± 0.7 | 1.4 ± 0.5 | 0.07 | 0.18 | 0.88 |
| RBC (x10^12/L) | 4.5 ± 0.3 | 4.5 ± 0.5 | 4.4 ± 0.5 | 0.83 | 0.16 | 0.35 |
| WBC (x10^9/L) | 7.2 ± 2.1 | 7.1 ± 2.4 | 8.0 ± 2.5 | 0.89 | 0.23 | 0.25 |
| Platelets (x10^9/L) | 206.6 ± 46.0 | 211.9 ± 63.5 | 188.6 ± 47.4 | 0.68 | 0.19 | 0.20 |
| Neutrophiles (x10^9/L) | 4.6 ± 1.6 | 4.7 ±2.3 | 5.6 ± 2.6 | 0.76 | 0.08 | 0.23 |
| Lymphocytes (x10^9/L) | 1.8 ± 0.6 | 1.6 ± 0.6 | 1.6 ± 0.8 | 0.32 | 0.35 | 0.83 |
| NLR | 2.7 ± 1.0 | 3.5 ± 3.6 | 6.7 ± 9.9 | 0.22 | **0.018** | 0.11 |
| Troponin (ng/L) | 769.9 ± 505.5 | 858.2 ± 704.0 | 822.6 ± 563.5 | 0.56 | 0.73 | 0.86 |
| Creatine (mmol/L) | 85.5 ± 17.0 | 80.8 ± 24.8 | 94.6 ± 31.3 | 0.35 | 0.17 | 0.10 |
| Urea (mmol/L) | 6.4 ± 1.9 | 6.3 ± 1.9 | 7.5 ± 3.0 | 0.81 | 0.12 | 0.12 |

NYHA=New York Heart Association, BMI=Body mass index, HDL=high-density lipoprotein, LDL=low-density lipoprotein, LVEF=Left ventricular ejection fraction, LVEDP=left ventricular end diastolic pressure, HFpEF=Heart failure with preserved ejection fraction, T2DM=type 2 diabetes mellitus, TG=triglycerides, RBC=red blood cells, WBC=white blood cells (leukocytes), Neutro=Neutrophiles, Lympho= Lymphocytes, NLR=Neutrophiles Lymphocytes ratio. p-value for continuous variable (BMI, LVEF, LVEDP, Hemoglobin, Hematocrit, HbA1c, Cholesterol, HDL, LDL, Triglycerides, RBC, Troponin, Creatine, WBC, Neutrophiles, Lymphocytes, NLR, Urea) expressed as mean ±SD, p-value calculated using t-test. Categorical variable (Sex, BMI Class, and NYHA) expressed as number of cases (percentage of group), p-value calculated using Chi-square test. Significant p-value of <0.05 are bolded.



**Supplemental Figure 4 - rs551238 genotype correlations with clinical parameters.**

The clinical parameter is indicated above each graph with normal and abnormal ranges indicated within the graph by background colour. Outliers removed from statistical analysis (by ROUT test or outside limits of detection) are indicated by circles. Hb=hemoglobin, Hct=hematocrit, HDL=high-density lipoprotein, LDL=low-density lipoprotein, LVEF=left ventricular ejection fraction, LVEDP=left ventricular end diastolic pressure, and NLR=neutrophile to lymphocyte ratio. Statistical significance determined by student t-test.

**Supplemental Table 6- Haplotype associations with clinical phenotypes.**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Haplotype | HFpEF | | | T2DM | | | |
|  | Frequency | OR (95% CI) | p-value | | Frequency | OR (95% CI) | p-value |
| AAT | 0.5674 | 1.00 | n/a | 0.5673 | | 1.00 | n/a |
| CGG | 0.3826 | 1.51 (0.64-3.56) | 0.35 | 0.3844 | | 0.99 (0.51-1.91) | 0.97 |
| CGT | 0.292 | 0.68 (0.02-27.15) | 0.84 | 0.0301 | | 0.26 (0.02-2.82) | 0.27 |
| GHA p-value | 0.34 | | | 0.8 | | | |

GHA=global haplotype association, T2DM=Type 2 Diabetes mellitus, HFpEF=Heart Failure with preserved ejection fraction, OR=Odds ratio

**Supplemental Table 7- Sex differences in SNPs correlations with phenotypes**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | T2DM | | | | HFpEF | | | |
| S | Geno. | Cases | Controls | OR (95% CI) | Int. | Cases | Controls | OR (95% CI) | Int. |
| rs1617640 | | | | | | | | | |
| F | A/A | 1 | 8 | 1.00 | 0.8 | 7 | 2 | 1.00 | 0.48 |
| A/C | 4 | 8 | 4.83 (0.37-63.55) | 9 | 3 | 1.01 (0.11-9.48) |
| C/C | 1 | 8 | 0.80 (0.03-18.12) | 8 | 1 | 2.54 (0.15-43.18) |
| M | A/A | 10 | 19 | 1.00 | 23 | 6 | 1.00 |
| A/C | 11 | 9 | 1.96 (0.56-6.88) | 18 | 2 | 2.94 (0.48-18.14) |
| C/C | 5 | 10 | 0.61 (0.14-2.64) | 11 | 4 | 1.13 (0.13-4.48) |
| rs507392 | | | | | | | | | |
| F | A/A | 1 | 6 | 1.00 | 0.97 | 5 | 2 | 1.00 | 0.48 |
| A/G | 2 | 8 | 1.13 (0.06-21.74) | 9 | 1 | 3.62 (0.20-66.26) |
| G/G | 1 | 6 | 0.45 (0.01-14.55) | 7 | 0 | n/a |
| M | A/G | 10 | 19 | 1.00 | 23 | 6 | 1.00 |
| G/G | 11 | 10 | 1.61 (0.46-5.67) | 18 | 3 | 1.90 (0.37-9.73) |
| C/C | 4 | 8 | 0.63 (0.13-3.02) | 10 | 2 | 2.01 (0.27-15.06) |
| rs551238 | | | | | | | | | |
| F | T/T | 1 | 7 | 1.00 | 0.9 | 5 | 3 | 1.00 | 0.26 |
| T/G | 3 | 8 | 2.79 (0.18-43.94) | 10 | 1 | 7.30 (0.48-111.05) |
| G/G | 1 | 5 | 1.14 (0.04-32.91) | 6 | 0 | n/a |
| M | T/T | 12 | 20 | 1.00 | 26 | 6 | 1.00 |
| T/G | 10 | 10 | 1.40 (0.40-4.92) | 17 | 3 | 1.67 (0.32-8.67) |
| G/G | 4 | 7 | 0.63 (0.13-3.10) | 9 | 2 | 1.78 (0.23-13.69) |

S=sex, F=female, M=male, Geno.=genotype, OR=odds ratio, Ctrl.=controls, int=interaction p-value, T2DM=Type 2 diabetes mellites, HFpEF=Heart failure with preserved ejection fraction

**Supplemental Table 8 - Other variants identified by Sanger sequencing**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Variants | Total | Anemia | Dyslipidemia | T2DM | HFpEF | Hypertension |
| -681C>T | 1 | 0 | 0 | 0 | 1 | 0 |
| -591C>T | 12 | 4 | 8 | 7 | 11 | 9 |
| -500G>T | 1 | 1 | 1 | 1 | 0 | 1 |
| -494T>G | 1 | 1 | 1 | 1 | 0 | 1 |
| -454T>C | 1 | 1 | 0 | 0 | 0 | 0 |
| -433T>A | 1 | 1 | 0 | 0 | 0 | 0 |
| -428G>A | 1 | 1 | 0 | 0 | 1 | 1 |
| -422G>A | 2 | 1 | 1 | 0 | 1 | 1 |
| 673A>G | 1 | 1 | 1 | 1 | 1 | 1 |
| 1775A>G | 2 | 0 | 2 | 2 | 1 | 2 |
| 1789insA | 3 | 1 | 2 | 2 | 3 | 3 |
| 1797insA | 1 | 0 | 0 | 0 | 0 | 1 |
| 1817G>A | 4 | 1 | 4 | 3 | 4 | 4 |
| 1826G>A | 1 | 0 | 1 | 1 | 1 | 1 |
| 2159C>T | 6 | 3 | 3 | 1 | 6 | 4 |
| 2163C>T | 6 | 3 | 3 | 1 | 6 | 4 |
| 2167?-2170?del1 | 76 | 19 | 56 | 24 | 63 | 57 |
| 2167?-2170?del2 | 4 | 1 | 3 | 3 | 4 | 4 |
| 2237G>A | 1 | 0 | 1 | 1 | 1 | 1 |
| 2374C>A | 1 | 0 | 1 | 0 | 0 | 0 |
| 2376insC | 1 | 1 | 1 | 0 | 1 | 1 |
| 2384C>A | 1 | 0 | 1 | 0 | 1 | 1 |
| 2397C>T | 1 | 0 | 1 | 1 | 0 | 1 |
| 2404G>A | 1 | 1 | 1 | 1 | 1 | 1 |
| 3107C>T | 3 | 1 | 2 | 1 | 3 | 2 |
| 3132insG | 1 | 1 | 1 | 0 | 1 | 1 |
| 3136G>A | 1 | 0 | 1 | 0 | 0 | 1 |
| 3149C>G | 1 | 0 | 0 | 0 | 1 | 1 |
| 3150T>A | 1 | 0 | 1 | 0 | 0 | 1 |
| 3154T>G | 77 | 20 | 55 | 26 | 62 | 56 |
| 3154T>G | 6 | 1 | 3 | 4 | 6 | 5 |
| 3194G>C | 1 | 0 | 1 | 1 | 1 | 1 |
| 3289T>A | 1 | 0 | 1 | 1 | 1 | 1 |
| 3300T>A | 1 | 0 | 1 | 1 | 1 | 1 |
| 3324G>A | 1 | 0 | 1 | 1 | 1 | 1 |
| 3363insT | 1 | 0 | 1 | 0 | 0 | 1 |
| 3434C>T | 4 | 1 | 3 | 0 | 3 | 3 |
| 3573C>A | 1 | 0 | 1 | 1 | 1 | 1 |
| 3606insG | 1 | 0 | 1 | 1 | 1 | 1 |
| 3786C>T | 1 | 0 | 1 | 0 | 0 | 1 |
| 3793insC | 1 | 0 | 1 | 0 | 0 | 1 |
| 3798C>T | 1 | 1 | 0 | 0 | 1 | 0 |
| 3806T>C | 2 | 0 | 2 | 0 | 2 | 2 |
| 3806T>C | 31 | 9 | 23 | 12 | 26 | 25 |
| 3833insA | 1 | 0 | 1 | 0 | 0 | 1 |
| 3747insA | 2 | 0 | 1 | 1 | 2 | 2 |
| 3892G>A | 2 | 0 | 1 | 0 | 1 | 1 |
| 3892insC | 1 | 0 | 1 | 0 | 0 | 1 |
| 3948T>G | 1 | 0 | 1 | 0 | 1 | 1 |
| 3976G>T | 1 | 1 | 0 | 1 | 1 | 1 |

ins=insertion, del=deletion, T2DM=type 2 diabetes mellites, HFpEF=heart failure with preserved ejection fraction

1-deletion is heterozygous

2-deletion is homozygous

**References**

1. Khabour OF, Bani-Ahmad MA, Hammash NM. Association between polymorphisms in erythropoietin gene and upper limit haematocrit levels among regular blood donors. *Transfus. Clin. Biol.* 2012;19(6):353–357.

2. Abhary S, Burdon KP, Casson RJ, et al. Association between erythropoietin gene polymorphisms and diabetic retinopathy. *Arch. Ophthalmol.* 2010;128(1):102–106.

3. Alwohhaib M, Alwaheeb S, Alyatama N, et al. Single nucleotide polymorphisms at erythropoietin, superoxide dismutase 1, splicing factor, arginine/serin-rich 15 and plasmacytoma variant translocation genes association with diabetic nephropathy. *Saudi J. Kidney Dis. Transpl.* 2014;25(3):577–581.

4. Fan YF, Fu YY, Chen Z, Hu YY, Shen J. Gene–gene interaction of erythropoietin gene polymorphisms and diabetic retinopathy in Chinese Han. *Exp. Biol. Med.* 2016;241(14):1524–1530.

5. Kaur N, Singh IR, Vanita V. Association of Erythropoietin Gene Polymorphisms With Type 2 Diabetic Retinopathy in Adult Patients From Northern India. *Can. J. Diabetes*. 2021;45(8):785–791.

6. Li H, Xu H, Li Y, Zhao D, Ma B. Associations between erythropoietin polymorphisms and risk of diabetic microvascular complications. *Oncotarget*. 2017;8(68):112675–112684.

7. Liu C, Bai GL, Liu P, Wang L. Role of EPO and TCF7L2 Gene Polymorphism Contribution to the Occurrence of Diabetic Retinopathy. *Dis. Markers*. 2022;2022:6900660.

8. Mankoč Ramuš S, Pungeršek G, Petrovič MG, Petrovič D. The GG genotype of erythropoietin rs1617640 polymorphism affects the risk of proliferative diabetic retinopathy in Slovenian subjects with type 2 diabetes mellitus: enemy or ally? *Acta Ophthalmol.* 2021;99(8):e1382–e1389.

9. Sesti LFC, Sbruzzi RC, Polina ER, et al. Association of polymorphisms in the erythropoietin gene with diabetic retinopathy: a case–control study and systematic review with meta-analysis. *BMC Ophthalmol.* 2022;22(1):250.

10. Tong Z, Yang Z, Patel S, et al. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. *Proc. Natl. Acad. Sci. U. S. A.* 2008;105(19):6998–7003.

11. Montesanto A, Rita Bonfigli A, De Luca M, et al. Erythropoietin (EPO) haplotype associated with all-cause mortality in a cohort of Italian patients with Type-2 Diabetes opeN. *Sci. Rep.* 2019;9:10395.

12. Renner W, Kaiser M, Khuen S, et al. The erythropoetin rs1617640 gene polymorphism associates with hemoglobin levels, hematocrit and red blood cell count in patients with peripheral arterial disease. *Genes (Basel).* 2020;11(11):1–6.

13. Ma W, Kantarjian H, Zhang K, et al. Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome. *BMC Med. Genet.* 2010;11:163.

14. Kästner A, Grube S, El-Kordi A, et al. Common Variants of the Genes Encoding Erythropoietin and Its Receptor Modulate Cognitive Performance in Schizophrenia. *Mol. Med.* 2012;18(1):1029–40.

15. Chiou TTY, Lee JJ, Wang MC, et al. Genetic disposition and modifiable factors independently associated with anemia in patients with type 2 diabetes mellitus. *Diabetes Res. Clin. Pract.* 2015;108(1):164–169.

16. Popov AF, Schulz EG, Schmitto JD, et al. Relation between renal dysfunction requiring renal replacement therapy and promoter polymorphism of the erythropoietin gene in cardiac surgery. *Artif. Organs*. 2010;34(11):961–968.

17. Zheng Y, Deng Z, Tang M, Cai P. Erythropoietin promoter polymorphism is associated with treatment efficacy and severe hematologic toxicity for platinum-based chemotherapy. *Expert Opin. Drug Metab. Toxicol.* 2021;17(4):495–502.

18. Song Q, Zhang Y, Wu Y, Zhou F, Qu Y. Association of erythropoietin gene polymorphisms with retinopathy in a Chinese cohort with type 2 diabetes mellitus. *Clin. Exp. Ophthalmol.* 2015;43(6):544–549.

19. Sobrin L, Green T, Sim X, et al. Candidate gene association study for diabetic retinopathy in persons with type 2 diabetes: The candidate gene association resource (CARe). *Investig. Ophthalmol. Vis. Sci.* 2011;52(10):7593–7602.

20. Xu J, Li H, Huang J, et al. Erythropoietin Gene Polymorphism rs551238 is Associated with a Reduced Susceptibility to Brain Injury in Preterm Infants. *Curr. Neurovasc. Res.* 2019;16(4):335–339.